OSMR (F9Q2W) Rabbit Monoclonal Antibody #95443

OSMR, also known as oncostatin-M-specific receptor subunit beta or interleukin-31 receptor subunit beta, is a member of the type I cytokine receptor family (1,2). This protein heterodimerizes with interleukin signal transducers, such as gp130, to form the binding receptor of oncostatin M (OSM) protein (3). Binding of the OSM ligand to OSMR complexes triggers activation of Jak1 and Jak2, which phosphorylate tyrosine residues in the cytoplasmic domains of both gp130 and OSMR. Downstream signaling along the Jak1 pathway leads to activation of the MAPK cascade, PI3K cascade, and STAT3 (4,5). OSMR activation of the STAT3/SMAD3 axis regulates expression of genes responsible for inducing a mesenchymal/cancer stem cell phenotype (6). Research studies have shown that OSMR is overexpressed in several cancer types and may be associated with adverse clinical outcomes (7,8). Because its expression is more restricted to stromal and other nonhaematopoietic cells, targeting OSMR may provide a novel means of inhibiting inflammatory pathology while preserving protective immunity (5).